Are people with a shorter history of viral suppression at greater risk of failure of dolutegravir/lamivudine?
Zambian patients on dolutegravir and recycled tenofovir regimens have high risk of TB even after switch
Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
World’s largest HIV treatment programme could shift almost entirely to WHO-preferred first line regimen
17 months average wait to switch from a failing HIV treatment regimen in African countries
Top 5 HIV treatment stories from CROI 2022
Top 5 stories on HIV treatment and care in Africa from CROI 2022
Further evidence that recycling tenofovir in second-line treatment is effective
Dolutegravir-based regimens result in sustained viral suppression, despite lower adherence and treatment interruptions
